Neurology
-
To determine whether preventive trials in genetic prion disease could be designed to follow presymptomatic mutation carriers to onset of disease. ⋯ The characterization of biomarkers suitable to serve as surrogate endpoints will be essential for the prevention of genetic prion disease. Parameters such as longer trial duration, increased enrollment, and the use of historical controls in a postmarketing study could provide opportunities for subsequent determination of clinical benefit.